Peripheral tumor biomarkers to guide treatment for HPV-associated malignancies

A new review paper was published in Oncotarget’s Volume 14 on August 10, 2023, entitled, “Peripheral surrogates of tumor burden to guide chemotherapeutic and immunotherapeutic strategies for HPV-associated malignancies.”

Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic – Biotech Investments

Issuer: Mainz BioMed N.V. / Key word(s): Miscellaneous 05.03.2024 / 14:01 CET/CEST The issuer is solely responsible for the content of this announcement. Mainz Biomed

March 6, 2024

Flywheel Secures $54M for Medical AI Imaging Platform

by Jasmine Pennic 06/27/2023 Leave a Comment What You Should Know: Flywheel, a Minneapolis-based medical imaging data and AI platform raises $54M in Series D

June 27, 2023

Health tech investors are getting selective. Expect slow growth, consolidation

Venture firms backing health tech startups are telegraphing cautious optimism for 2024, advising startups to expect smaller and fewer checks as well as possible market

October 23, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.